{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:57:58Z","timestamp":1758819478731},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2000,10,1]],"date-time":"2000-10-01T00:00:00Z","timestamp":970358400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2000,10]]},"DOI":"10.1007\/s11864-000-0070-5","type":"journal-article","created":{"date-parts":[[2007,10,11]],"date-time":"2007-10-11T07:04:25Z","timestamp":1192086265000},"page":"423-432","source":"Crossref","is-referenced-by-count":1,"title":["Localized bladder cancer"],"prefix":"10.1007","volume":"1","author":[{"given":"Jonathan I.","family":"Izawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Barton","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"70_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/canjclin.50.1.7","volume":"50","author":"RT Greenlee","year":"2000","unstructured":"Greenlee RT, Murray T, Bolden S, et al.: Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"70_CR2","unstructured":"AJCC Cancer Staging Manual, edn 5. Philadelphia: Lippincott-Raven; 1997:241\u2013243."},{"key":"70_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0094-0143(05)70229-9","volume":"27","author":"R Lee","year":"2000","unstructured":"Lee R, Droller MJ: The natural history of bladder cancer. Urol Clin North Am 2000, 27:1\u201313.","journal-title":"Urol Clin North Am"},{"key":"70_CR4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0022-5347(17)51695-X","volume":"130","author":"NM Heney","year":"1983","unstructured":"Heney NM, Ahmed S, Flanagan J, et al.: Superficial bladder cancer: progression and recurrence. J Urol 1983, 130:1083\u20131086.","journal-title":"J Urol"},{"key":"70_CR5","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0022-5347(17)45923-4","volume":"186","author":"JM Fitzpatrick","year":"1986","unstructured":"Fitzpatrick JM, West AB, Butler MR, et al.: Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 1986, 186:920\u2013922.","journal-title":"J Urol"},{"key":"70_CR6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1046\/j.1464-410x.1998.00628.x","volume":"81","author":"P Allard","year":"1998","unstructured":"Allard P, Bernard P, Fradet Y, et al.: The early clinical course of primary Ta and T1 bladder cancer: a proposed' prognostic index. Br J Urol 1998, 81:692\u2013698.","journal-title":"Br J Urol"},{"key":"70_CR7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/(SICI)1098-2388(199709\/10)13:5<291::AID-SSU2>3.0.CO;2-8","volume":"13","author":"SL Johansson","year":"1997","unstructured":"Johansson SL, Cohen SM: Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997, 13:291\u2013298.","journal-title":"Semin Surg Oncol"},{"key":"70_CR8","first-page":"3603","volume":"58","author":"JA Taylor","year":"1998","unstructured":"Taylor JA, Umbach DM, Stephens E, et al.: The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 1998, 58:3603\u20133610.","journal-title":"Cancer Res"},{"key":"70_CR9","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/85.14.1159","volume":"85","author":"DA Bell","year":"1993","unstructured":"Bell DA, Taylor JA, Paulson DF, et al.: Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993, 85:1159\u20131164.","journal-title":"J Natl Cancer Inst"},{"key":"70_CR10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJM199203123261104","volume":"326","author":"D Sidransky","year":"1992","unstructured":"Sidransky D, Frost P, von Eschenbach A, et al.: Clonal origin of bladder cancer. N Engl J Med 1992, 326:737\u2013740. This important study provided strong evidence that multiple bladder tumors can arise from a single transformed cell by analyzing X-chromosome inactivation and allelic loss in cystectomy specimens.","journal-title":"N Engl J Med"},{"key":"70_CR11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3322\/canjclin.48.5.269","volume":"48","author":"MJ Droller","year":"1998","unstructured":"Droller MJ: Bladder cancer: state-of-the-art care. CA Cancer J Clin 1998, 48:269\u2013283.","journal-title":"CA Cancer J Clin"},{"key":"70_CR12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0094-0143(21)00413-4","volume":"19","author":"RB Cummings","year":"1992","unstructured":"Cummings RB, Barone JG, Ward WS: Diagnosis and staging of bladder cancer. Urol Clin North Am 1992, 19:455\u2013465.","journal-title":"Urol Clin North Am"},{"key":"70_CR13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/(SICI)1097-0142(19990625)87:3<118::AID-CNCR4>3.0.CO;2-N","volume":"87","author":"S Bastacky","year":"1999","unstructured":"Bastacky S, Ibrahim S, Wilczynski SP, et al.: The accuracy of cytology in daily practice. Cancer 1999, 87:118\u2013128.","journal-title":"Cancer"},{"key":"70_CR14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0094-0143(05)70230-5","volume":"27","author":"JM Hozbeierlein","year":"2000","unstructured":"Hozbeierlein JM, Smith Jr JA: Surgical management of noninvasive bladder cancer (stages Ta\/T1\/CIS). Urol Clin North Am 2000, 27:15\u201324.","journal-title":"Urol Clin North Am"},{"key":"70_CR15","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJM199905063401803","volume":"340","author":"DS Michaud","year":"1999","unstructured":"Michaud DS, Spiegelman D, Clinton SK, et al.: Fluid intake and the risk of bladder cancer in men. N Engl J Med 1999, 340:1390\u20131397. This well-designed prospective study provided data that supports increased fluid intake as a preventive strategy against the development of bladder cancer.","journal-title":"N Engl J Med"},{"key":"70_CR16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000475068","volume":"28","author":"UE Studer","year":"1995","unstructured":"Studer UE, Jenzer S, Biedermann C, et al.: Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Eur Urol 1995, 28:284\u2013290.","journal-title":"Eur Urol"},{"key":"70_CR17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-5347(17)34863-2","volume":"151","author":"DL Lamm","year":"1994","unstructured":"Lamm DL, Riggs DR, Shriver JS, et al.: Megadose vitamins in bladder cancer: a double blind clinical trial. J Urol 1994, 151:21\u201326.","journal-title":"J Urol"},{"key":"70_CR18","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","volume":"13","author":"HW Herr","year":"1995","unstructured":"Herr HW, Schwalb DM, Zhang Z, et al.: Intravesical bacillus Calmette-Gu\u00e9rin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995, 13:1404\u20131408. This randomized prospective study with 10-year follow-up showed that the use of BCG in patients with recurrent superficial bladder TCC can delay tumor progression.","journal-title":"J Clin Oncol"},{"key":"70_CR19","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, et al.: Maintenance BCG immunotherapy in recurrent Ta, T1, and carcinoma in situ transitional cell carcinoma: a randomized Southwest Oncology Group Study. J Urol 2000, 163:1124\u20131129. This large randomized study demonstrates the superiority of intensive maintenance BCG in improving time to recurrence and time to progression (worsening free survival).","journal-title":"J Urol"},{"key":"70_CR20","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","volume":"156","author":"S Krege","year":"1996","unstructured":"Krege S, Giani G, Meyer R, et al.: A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Gu\u00e9rin. J Urol 1996, 156:962\u2013966.","journal-title":"J Urol"},{"key":"70_CR21","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0022-5347(01)67608-0","volume":"153","author":"CH Bouffioux","year":"1995","unstructured":"Bouffioux CH, Kurth KH, Bono A, et al.: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol 1995, 153:934\u2013941.","journal-title":"J Urol"},{"key":"70_CR22","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0022-5347(01)61606-9","volume":"161","author":"E Solsona","year":"1999","unstructured":"Solsona E, Iborra I, Ricos JV, et al.: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999, 161:1120\u20131123.","journal-title":"J Urol"},{"key":"70_CR23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0094-0143(05)70240-8","volume":"27","author":"JLF Duque","year":"2000","unstructured":"Duque JLF, Loughlin KR: An overview of the treatment of superficial bladder cancer. Urol Clin North Am 2000, 27:125\u2013135. This is a timely review that provides a brief yet comprehensive review of intravesical chemotherapy for the treatment of superficial bladder cancer.","journal-title":"Urol Clin North Am"},{"key":"70_CR24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0094-0143(05)70245-7","volume":"27","author":"DH Brown","year":"2000","unstructured":"Brown DH, Wagner TT, Bahnson RR: Interferons and bladder cancer. Urol Clin North Am 2000, 27:171\u2013178.","journal-title":"Urol Clin North Am"},{"key":"70_CR25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0094-0143(05)70241-X","volume":"27","author":"G Dalbagni","year":"2000","unstructured":"Dalbagni G, Herr HW: Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am 2000, 27:137\u2013146.","journal-title":"Urol Clin North Am"},{"key":"70_CR26","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0022-5347(01)63160-4","volume":"159","author":"AS Belldegrun","year":"1998","unstructured":"Belldegrun AS, Franklin JR, O'Donnell MA, et al.: Superficial bladder cancer: the role of interferon-a. J Urol 1998, 159:1793\u20131801.","journal-title":"J Urol"},{"key":"70_CR27","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0022-5347(01)61609-4","volume":"161","author":"P Rajala","year":"1999","unstructured":"Rajala P, Liukkonen T, Raitanen M, et al.: Transurethral resection with perioperative instillation of interferona or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study\u2014Finnbladder III. J Urol 1999, 161:1133\u20131136.","journal-title":"J Urol"},{"key":"70_CR28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0090-4295(97)00303-8","volume":"50","author":"JF Jimenez-Cruz","year":"1997","unstructured":"Jimenez-Cruz JF, Vera-Donoso CD, Leiva O, et al.: Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): multicenter trial comparing bacille Calmette-Gu\u00e9rin and interferonalpha. Urology 1997, 50:529\u2013535.","journal-title":"Urology"},{"key":"70_CR29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1994.12.1.7","volume":"12","author":"F Boccardo","year":"1994","unstructured":"Boccardo F, Cannata D, Rubagotti A, et al.: Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. J Clin Oncol 1994, 12:7\u201313.","journal-title":"J Clin Oncol"},{"key":"70_CR30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1046\/j.1464-410x.2000.00566.x","volume":"85","author":"CN Sternberg","year":"2000","unstructured":"Sternberg CN, Calabro F: Chemotherapy and management of bladder tumours. BJU Int 2000, 85:599\u2013610.","journal-title":"BJU Int"},{"key":"70_CR31","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1200\/JCO.1998.16.4.1298","volume":"16","author":"HW Herr","year":"1998","unstructured":"Herr HW, Bajorin DF, Scher HI: Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998, 16:1298\u20131301.","journal-title":"J Clin Oncol"},{"key":"70_CR32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0022-5347(05)68582-5","volume":"162","author":"WU Shipley","year":"1999","unstructured":"Shipley WU, Kaufman DS, Heney NM, et al.: An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. J Urol 1999, 162:445\u2013450.","journal-title":"J Urol"},{"key":"70_CR33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0090-4295(99)00463-X","volume":"55","author":"AM Kamat","year":"1999","unstructured":"Kamat AM, Lamm DL: Intravesical therapy for bladder cancer. Urology 1999, 55:161\u2013168.","journal-title":"Urology"},{"key":"70_CR34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0094-0143(05)70238-X","volume":"27","author":"JT Hsieh","year":"2000","unstructured":"Hsieh JT, Dinney CP, Chung LW: The potential role of gene therapy in the treatment of bladder cancer. Urol Clin North Am 2000, 27:103\u2013113.","journal-title":"Urol Clin North Am"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-000-0070-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-000-0070-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-000-0070-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T17:10:25Z","timestamp":1629911425000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-000-0070-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,10]]}},"alternative-id":["70"],"URL":"https:\/\/doi.org\/10.1007\/s11864-000-0070-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,10]]}}}